Plasma Lipids, Apolipoproteins and Subsequent Cognitive Decline in Men with Coronary Heart Disease
2The Israel Center for Disease Control, Israel Ministry of Health
3School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa
4Department of Neurology, Sackler Faculty of Medicine, Tel Aviv University
Background: Lipid levels are associated with an increased risk of cardiovascular disease.
Objective: We investigated the association between plasma lipids, apolipoproteins levels, apolipoprotein B/low-density lipoprotein cholesterol (Apo-B/LDL-C) and Apo-B/Apo-A ratios and rate of cognitive decline two decades later in men with CHD.
Methods: A subset of 337 men (mean age at baseline 56.6±6.4 years) who previously participated in the Bezafibrate Infarction Prevention (BIP) trial (1990-1997) underwent cognitive evaluations 15±3 years (T1) and 19.9±1 years after baseline (T2) as part of the BIP Neurocognitive study. Lipid and apolipoprotein fractions were measured at baseline. Cognitive function for memory, executive function, visual spatial, attention domains and composite score were assessed using the NeuroTrax Computerized Battery at T1 and T2 evaluations. Linear mixed models were used to assess change in cognitive function between the two cognitive evaluations.
Results: Controlling for confounders, the decline in composite cognitive score (β=-0.161±0.06; p=0.013) as well as in memory (β=-0.269±0.10; p=0.009) and visual spatial function (β=-0.304±0.12; p=0.010) was greater among patients in the upper (≥105 mg/dL) Apo-B tertile as compared to counterparts with Conclusion: Our findings suggest that the plasma concentrations of Apo-B, LDL-C and Apo-B/LDL-C ratio are potential predictors of accelerated late-life cognitive decline among men with CHD.
Powered by Eventact EMS